Clinical Trial Detail

NCT ID NCT03865082
Title Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Idera Pharmaceuticals, Inc.

colorectal cancer

laryngeal squamous cell carcinoma

oropharynx cancer

hypopharynx cancer

oral squamous cell carcinoma


IMO-2125 + Ipilimumab + Nivolumab

Age Groups: senior adult

Additional content available in CKB BOOST